# Survodutide

> Survodutide is an investigational dual GLP-1/glucagon receptor agonist being studied for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Phase 2 trials have reported meaningful average body-weight reductions alongside improvements in liver-related markers. It has not yet received regulatory approval and remains in late-stage clinical development. Evidence is currently limited to trial populations, and broader safety and efficacy data are still accumulating.

- URL: https://www.lifeconverted.com/peptides/survodutide
- Also known as: BI 456906
- Primary category: Weight Management
- Effectiveness rank: #19 in Weight Management
- Evidence level: Moderate evidence
- Route: Subcutaneous
- Dose range: 0.6-6 mg
- Dose tiers: low 0.6 mg; moderate 2.4 mg; high 6 mg
- Half-life: Approximately 5-6 days, consistent with once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous use with titration over several months in trial protocols on, Not established outside of trial settings off
- Storage: Refrigerate at 2-8°C; protect from light; do not freeze.

## Mechanism of action

Survodutide activates GLP-1 receptors, producing appetite suppression and slowed gastric emptying, alongside glucagon receptor activation, which is thought to increase hepatic fat oxidation and energy expenditure. The combined action is intended to address both body weight and liver fat content, distinguishing it from single-pathway GLP-1 agents.

## Reported benefits

- Associated with meaningful average weight loss in phase 2 trials
- May reduce liver fat content in studied populations
- Once-weekly dosing schedule
- Dual-pathway mechanism distinct from GLP-1-only agents

## Reported side effects

- Nausea, vomiting, and diarrhea, especially during titration
- Decreased appetite
- Injection-site reactions
- Potential increases in heart rate reported in some trials
- Long-term safety data remain limited

## Common protocols

- Trial-based step-up titration schedule
- Once-weekly subcutaneous injection with site rotation

## Stacking notes

Not established; combination with other incretin-based agents is not supported by published research.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer